Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer

Huimin YU; Xin XIN; Zhiwei LIANG

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 >

Huimin YU, Xin XIN, Zhiwei LIANG. Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University.

Citation:

Huimin YU, Xin XIN, Zhiwei LIANG. Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University.

Huimin YU, Xin XIN, Zhiwei LIANG. Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University.

Citation:

Huimin YU, Xin XIN, Zhiwei LIANG. Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University.

PDF( 813 KB)

Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer

1.
Intervention Department，Shijiazhuang Third Hospital，Shijiazhuang Hebei 050000
2.
Department of Thoracic Surgery，Fengfeng General Hospital，North China Medical and Health Group, Handan Hebei 056200，China

Received Date: 2024-05-28

Abstract

Abstract

Objective To explore the expression changes of KIAA1199 and Linc00673 genes in non-small cell lung cancer patients before and after chemotherapy, and to further evaluate the potential value of these two genes as molecular markers in predicting chemotherapy efficacy. Methods : A total of 58 patients with stage Ⅲ-Ⅳ NSCLC admitted to the Third Hospital of Shijiazhuang and Fengfeng General Hospital of North China Medical Health Group from August 2019 to August 2021 were selected. Peripheral blood PBMCs were collected from patients 2 days before treatment and after two cycles of treatment to detect the expression levels of KIAA1199 and Linc00673 genes. The chemotherapy efficacy of patients was statistically analyzed, and the value of KIAA1199 and Linc00673 genes as molecular markers in predicting chemotherapy efficacy was assessed using ROC curve analysis. Results After 2 cycles of chemotherapy, 20 out of 58 patients showed disease progression, accounting for 34.48%. qPCR results showed no statistically significant difference in the expression levels of KIAA1199 and Linc00673 genes between progressed and non-progressed patients before treatmen （P > 0.05）. After treatment, the expression levels of KIAA1199 and Linc00673 genes were significantly lower in non-progressed patients compared to progressed patients （P < 0.01）. ROC curve analysis showed that the AUC of combined detection was significantly higher than that of KIAA1199 gene and Linc00673 gene alone （Z = 3.054, 5.178, P < 0.05）. Conclusion In NSCLC patients undergoing chemotherapy, the expression of KIAA1199 and Linc00673 genes shows significant differences based on therapeutic efficacy, with KIAA1199 being more suitable as a biomarker for predicting chemotherapy efficacy.
- Linc00673,
- KIAA1199,
- Non small cell lung cancer,
- Expression level,
- Efficacy prediction

FullText(HTML)

References(24)

References

[1]	Tang A,Ahmad U,Toth AJ,et al. Non-small cell lung cancer in never- and ever-smokers: Is it the same disease? [J]. J Thorac Cardiovasc Surg,2021,161(6): 1903-1917. e9.
[2]	Alexander M,Kim S Y,Cheng H Y. Update 2020: Management of non-small cell lung cancer[J]. Lung,2020,198(6):897-907. doi: 10.1007/s00408-020-00407-5
[3]	Zhou C C,Chen G Y,Huang Y C,et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised,open-label,multicentre,phase 3 trial[J]. Lancet Respir Med,2021,9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9
[4]	Imyanitov E N,Iyevleva A G,Levchenko E V. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives[J]. Crit Rev Oncol Hematol,2021,157:103194. doi: 10.1016/j.critrevonc.2020.103194
[5]	Redman M W,Papadimitrakopoulou V A,Minichiello K,et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): A biomarker-driven master protocol[J]. Lancet Oncol,2020,21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7
[6]	Ito K,Nishida Y,Ikuta K,et al. Overexpression of KIAA1199,a novel strong hyaluronidase,is a poor prognostic factor in patients with osteosarcoma[J]. J Orthop Surg Res,2021,16(1):439. doi: 10.1186/s13018-021-02590-4
[7]	Liu JM,Yan W,Han P,et al. The emerging role of KIAA1199 in cancer development and therapy[J]. Biomed Pharmacother,2021,138:111507. doi: 10.1016/j.biopha.2021.111507
[8]	Qiao K,Ning S P,Wan L,et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway[J]. J Exp Clin Cancer Res,2019,38(1):418 doi: 10.1186/s13046-019-1421-7
[9]	Lu W,Zhang H H,Niu Y Q,et al. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation,migration,invasion and epithelial mesenchymal transition by sponging miR-150-5p[J]. Mol Cancer,2017,16(1):118. doi: 10.1186/s12943-017-0685-9
[10]	Guan H Y,Zhu T,Wu S S,et al. Long noncoding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/β-catenin signaling[J]. Proc Natl Acad Sci U S A,2019,116(28):14019-14028. doi: 10.1073/pnas.1900997116
[11]	Schrank B R,Colbert L E. Genomic biomarkers predict response to combined ATR inhibition and radiotherapy[J]. Clin Cancer Res,2024.
[12]	Ebrahimpour L,Lemaréchal Y,Yolchuyeva S,et al. The impact of radiomics libraries and gray level discretization on the discovery of immunotherapy biomarkers in NSCLC patients[J] . Br J Radiol,2024: tqae187.
[13]	Tang Z Y,Ding Y,Shen Q,et al. KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT[J]. J Mol Med (Berl),2019,97(1):127-140. doi: 10.1007/s00109-018-1721-y
[14]	Baran K,Kordiak J,Jabłoński S,et al. Panel of miR-150 and linc00673,regulators of CCR6/CCL20 may serve as non-invasive diagnostic marker of non-small cell lung cancer[J]. Scientific Reports,2023,13(1):9642-9642. doi: 10.1038/s41598-023-36485-7
[15]	Yao Y,Zhao Q,Xu F,et al. Enhanced anti-tumor therapy for hepatocellular carcinoma via sorafenib and KIAA1199-siRNA co-delivery liposomes[J]. Saudi Pharm J,2024,32(9):102153. doi: 10.1016/j.jsps.2024.102153
[16]	Zhu YR,Zhang ZF,Peng H,et al. Clinicopathological and prognostic significance of LINC00673 in human malignancy: A review and meta-analysis[J]. Biosci Rep,2021,41(7):BSR20211175. doi: 10.1042/BSR20211175
[17]	Shen X J,Mo X C,Tan W D,et al. KIAA1199 correlates with tumor microenvironment and immune infiltration in lung adenocarcinoma as a potential prognostic biomarker[J]. Pathol Oncol Res,2022,28:1610754. doi: 10.3389/pore.2022.1610754
[18]	Zhang Y B,Yu H L,Guo Z. Circ_KIAA1199 inhibits MSI1 degradation by targeting miR-34c-5p to drive the malignant cell behaviors and tumor growth of colorectal cancer[J]. Anticancer Drugs,2022,33(1):e134-e144. doi: 10.1097/CAD.0000000000001164
[19]	Zhu K J,Gong Z J,Li P C,et al. A review of linc00673 as a novel lncRNA for tumor regulation[J]. Int J Med Sci,2021,18(2):398-405. doi: 10.7150/ijms.48134
[20]	Shen S Y,Yang C Q,Liu X B,et al. RBFOX1 regulates the permeability of the blood-tumor barrier via the LINC00673/MAFF pathway[J]. Mol Ther Oncolytics,2020,17:138-152. doi: 10.1016/j.omto.2020.03.014
[21]	Li N,Cui Z G,Huang D Y,et al. Association of LINC00673 rs11655237 polymorphism with cancer susceptibility: A meta-analysis based on 23478 subjects[J]. Genomics,2020,112(6):4148-4154. doi: 10.1016/j.ygeno.2020.07.015
[22]	Wang S S,Chao J S,Wang H,et al. Effectiveness,safety,and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: A real-world study[J]. Cancer Immunol Immunother,2024,73(12):249. doi: 10.1007/s00262-024-03841-z
[23]	Zhou C C,Hu Y P,Arkania E,et al. 152P Exploratory biomarker analysis of phase Ⅲ ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer[J]. Annals of Oncology,2024,35(S2):S276-S276.
[24]	Solomon B,Wu L Y,Dziadziuszko R,et al. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)[J]. Annals of Oncology,2024,35(S2):S775-S775.

Relative Articles(20)

Relative Articles

[1]	Shengxi YANG, Jiade ZHU, Qiurui LI, Wenlian TU. Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Journal of Kunming Medical University,
[2]	Chao HONG, Xudong XIANG, Yingfu LI, Yang CAO, Xueya CHEN, Shuai LI, Anhao XING, Mu LIN, Qianli MA. Association of Polymorphisms in the 3' UTR of Genes in the ERK1/2 Signaling Pathway with Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240302
[3]	Caini ZHANG, Ya LI. A Meta-analysis of the Efficacy and Safety of Camrelizumab Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240610
[4]	Yan LIANG, Lei WANG, Ming LEI, Benchao CHEN, Ping SUN, Shuai LI, Li LIU, Qianrong WANG, Manlin LIAO, Qianli MA. Correlation between KRAS Gene Polymorphism and Non-small Cell Lung Cancer in Yunnan Han Population. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230210
[5]	Chuntao LI, Xuemei ZHANG, Yandi SU, Jianqing Zhang. Construction of Stable Transfected Cell Line A549 of Non-small Cell Lung Cancer by Overexpressing and Knocking Down LncRNA RP11-521C20.3. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231016
[6]	Jia YANG, Ya-xian LI, Ying-ying WANG, Lin XIAO, Chuan-yin LI, Fang TAN, Qian-li MA, Shu-yuan LIU. Association of the miR-149,miR-219 and miR-let-7 Polymorphisms with the Occurrence and Development of Non-small Cell Lung Cancer in a Chinese Han Population in Yunnan Province. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20211037
[7]	Ying-xia WANG, Qin HE, Guo-fang WANG, Xuan ZHANG. Expression and Significance of microRNA-21 and EGFR in Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210818
[8]	Chen Ben Chao , Li Heng , Liu Chao , Wang Shu Ting , Li Gao Feng . . Journal of Kunming Medical University,
[9]	Wang Juan , Su Guo Miao , Pan Guo Qing , Bian Li , Yang Zhe , Zeng Ding Tao . . Journal of Kunming Medical University,
[10]	Xiao-biao MA, Feng LUO, Yong-liang GAO, Jing-chao HAO. Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20201215
[11]	Hu Feng Di , Zhang Jian Qiang , Wang Chu , Luo Chun Xiang , Li Ke . Influence of CD151 Inhibition by RNAi on Lung Metastasis in Null Mice Given Tail Veins Injection of Lung Adenocarcinoma Cell Lines A549. Journal of Kunming Medical University,
[12]	Tang Shi Cong , Pan Hong , Huang Yao Yuan , Zhou Xin , Wang Shou Feng , Zuo Chuan Tian , Mao Nai Quan . . Journal of Kunming Medical University,
[13]	Liang Nai Chao . Correlation between Expression of MMP-9， TIMP-1 and VEGF and the Invasion of Non Small Cell Lung Cancer. Journal of Kunming Medical University,
[14]	Liu Jun . . Journal of Kunming Medical University,
[15]	Zhou JieYan . . Journal of Kunming Medical University,
[16]	. Thoracoscopic Lobectomy in the Treatment of 54 Patients with Non-small Cell Lung Cancer. Journal of Kunming Medical University,
[17]	. Relationship between Expression of CDK2 and p27kip1 Protein and Non-small Cell Lung Cancer in Xuanwei. Journal of Kunming Medical University,
[18]	. Clinical Effects of Double-way Chemotherapy on Non-small Cell Lung Cancer with Malignant Pericardial Effusion. Journal of Kunming Medical University,
[19]	Yang Fang . . Journal of Kunming Medical University,
[20]	Zhang Lan Feng . . Journal of Kunming Medical University,